Tennis star Iga Swiatek accepts one-month ban for failed doping test

Tennis star Iga Swiatek accepted a one-match suspension after testing positive for a banned substance in an out-of-competition test in August 2024, the International Tennis Integrity Agency said on Thursday, November 28.

Iga Swiatek, a five-time Grand Slam champion, tested positive for a prohibited substance -- trimetazidine (TMZ), which is used as a heart medication. However, the ITIA confirmed that there was no significant fault or negligence from the player's side and thus the one-month ban. Iga was provisionally suspended from September 12, 2024, before successfully appealing, missing three tournaments.

The failed doping test came weeks after Iga



Swiatek won a bronze medal at the Paris Olympics.

Investigations revealed that the prohibited substance originated from a contaminated regulated melatonin medication used for sleep and jet lag, which was manufactured and sold in Poland. The ITIA determined that Swiatek bore minimal responsibility, finding the fault to be at the lowest end of the “No Significant Fault or Negligence” category under the Tennis Anti-Doping Programme (TADP).

After crediting the provisional suspension time served, Swiatek's suspension will officially conclude on 4 December 2024. Swiatek forfeited prize money from the Cincinnati Open, which immediately followed the positive test.